linjc16/ctgov huggingface dataset:
Effects of Different Fresh Gas Flows on Carboxyhemoglobin Levels

Study Overview
=================
Brief Summary
-----------------
To observe the effect of different fresh flows (1 L / min and 4 L / min) on the carboxyhemoglobin level non-invasively and continuous measurement and to determine the contribution of smoking to the intraoperative carbon monoxide accumulation.

Official Title
-----------------
Effects of Different Fresh Gas Flows on Carboxyhemoglobin Levels: Noninvasive Carbon Monoxide Monitoring

Conditions
-----------------
Fresh Flow, Carboxyhemoglobinemia

Intervention / Treatment
-----------------
* Device: Radical-7 Pulse CO-Oximeter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II Undergo 2-4 hours of elective surgery Exclusion Criteria: Cardiovascular disease diabetes mellitus kidney, liver failure chronic obstructive pulmonary disease patients with opioid sensitivity morbidly obese personal or family history of malignant hyperthermia history of prolonged recovery from anesthesia alcohol addicted pregnant and breastfeeding women patients allergic to study drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High Flow anesthesia<br>administered 4 L/min fresh gas flow during general anesthesia | Device: Radical-7 Pulse CO-Oximeter<br>* COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)<br>|
| Low Flow Anesthesia<br>administered 1 L/min fresh gas flow during general anesthesia | Device: Radical-7 Pulse CO-Oximeter<br>* COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effects of different fresh gas flows on carboxyhemoglobin levels | To observe the effect of different fresh flows (1 L / min and 4 L / min) on the carboxyhemoglobin level by non-invasive and continuous measurement. | during surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effects of smoking on carbon monoxide accumulation. | to determine the contribution of smoking to intraoperative carbon monoxide accumulation. | during surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low flow anesthesia, Non-invasive carboxyhemoglobinemia monitoring, Smoking
The Effect of Systemic Lidocaine Infusion to Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children

Study Overview
=================
Brief Summary
-----------------
Systemic lidocaine administration may improve postoperative pain and recovery after laparoscopic inguinal hernia repair in pediatric patients

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Drug: Systemic intravenous lidocaine infusion
* Drug: Normal saline infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 1 and 6 year-old ASA class 1 and 2 Pediatric Inguinal hernia patients who are scheduled for elective laparoscopic inguinal hernia repair Exclusion Criteria: Allergy to local anesthetics or contraindication to use of lidocaine Current active upper respiratory infection or history of upper respiratory infection within 2 weeks Severe cardiovascular disease Renal failure Liver failure Neurologic and psychologic disease Chronic treatment with analgesics Previous history of laparoscopic operation Parents' refusal

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group L<br>Intravenous lidocaine infusion group | Drug: Systemic intravenous lidocaine infusion<br>* In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.<br>|
| Placebo Comparator: Group C<br>Intravenous normal saline infusion - control group | Drug: Normal saline infusion<br>* In group C, the patients receive same volume of normal saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessing postoperative pain | Assessing FLACC(Face-Legs-Activity-Crying-Consolability) score at 4, 8, 12 and 24hours after operation | 24 hours after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
systemic lidocaine, postoperative pain, recovery, pediatric, inguinal hernia, laparoscopy
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Official Title
-----------------
A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD

Conditions
-----------------
Macular Degeneration

Intervention / Treatment
-----------------
* Drug: Photrex (rostaporfin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Photrex (rostaporfin)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Angiographic changes |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Macular Degeneration, AMD, Visual Acuity
Diagnostic Yield of 20-gauge Procore Needle for EUS-guided FNA Biopsy in Solid Pancreatic Lesions

Study Overview
=================
Brief Summary
-----------------
This study aims to examine technical feasibility and diagnostic yield of new 20-gauge Procore needle for EUS-guided fine needle biopsy in solid lesions by comparing with 22-gauge Procore needle. The study design is prospective, randomized study.

Official Title
-----------------
Technical Feasibility and Diagnostic Yield of New 20-gauge Procore Needle for EUS-guided FNA Biopsy in Solid Pancreatic Lesions; Comparison With 22-gauge Procore Needle

Conditions
-----------------
Pancreatic Neoplasms

Intervention / Treatment
-----------------
* Device: EUS-FNB with 20 gauge ProCore needle
* Device: EUS-FNB with 22 gauge ProCore needle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 20 years referred to our medical center for EUS-FNB with diagnosed or suspected solid pancreatic masses according to clinical evaluation and imaging studies. Exclusion Criteria: cystic pancreatic lesions, patients haemodynamically unstable or with severe coagulopathy (international normalized ratio [INR] > 1.5 or platelet count < 50,000 cells/cubic millimeter [cmm3]), patients unable to suspend anticoagulant/anti-platelet therapy, pregnancy, inability or refusal to give informed consent, and refusal to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EUS-FNB with 20-gauge<br>EUS-FNB with 20-gauge procore needle | Device: EUS-FNB with 20 gauge ProCore needle<br>* EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)<br>|
| Active Comparator: EUS-FNB with 22-gauge<br>EUS-FNB with 22-gauge procore needle | Device: EUS-FNB with 22 gauge ProCore needle<br>* EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| single diagnostic yield of the histologic core |  | up to 5 minutes after endoscopic ultrasound-guided fine needle biopsy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total diagnostic yield of the histologic core |  | up to 5 minutes after endoscopic ultrasound-guided fine needle biopsy |
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals

Study Overview
=================
Brief Summary
-----------------
We hypothesized that providing physicians treating with HIV disease, at the time of a routine outpatient visit, with a detailed report describing patients' adherence with HIV antiretroviral medications, would improve the quality of the physician-patient interaction, and also patients' subsequent adherence.

Official Title
-----------------
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals

Conditions
-----------------
HIV Infection, HIV Infections

Intervention / Treatment
-----------------
* Behavioral: Adherence report


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: on ART willing to use MEMS cap speaks and reads English detectable viral loads Exclusion Criteria: uses a pill box

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Received report<br> | Behavioral: Adherence report<br>* During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.<br>|
| Placebo Comparator: Routine care<br>Patients receive usual, routine, care. | Behavioral: Adherence report<br>* During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antiretroviral medication adherence as assessed by electronic pill cap monitoring. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported medication adherence |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, antiretroviral therapy, medication adherence, Treatment Experienced
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae

Study Overview
=================
Brief Summary
-----------------
The study assesses patients with cured pulmonary tuberculosis by compulsory notification data of Uberlândia (Minas Gerais state - Brazil) from 2012, 2013, 2014 and 2015. These patients will be invited by telephonic contact. After eligibility and exclusion criteria evaluation, those included will be assessed in order to know structural and functional repercussions of pulmonary tuberculosis sequelae.

Detailed Description
-----------------
This study evaluates structural and functional repercussions of pulmonary tuberculosis sequelae by chest imaging (computed tomography and radiograph), functional respiratory tests (spirometry and six minute walking test) in patients with cured pulmonary tuberculosis.

Official Title
-----------------
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae

Conditions
-----------------
Pulmonary Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pulmonary tuberculosis with completed treatment (patients that received at least six months of treatment and with confirmed cure by negative culture and/or sputum smear, or clinical and radiological improvement after well succeed treatment); Treatment finalized at least one year before. Exclusion Criteria: Physically impaired to perform the functional tests; Coexisting lung pathology (history of previous respiratory disease or clinical or radiological evidence of lung disease other than tuberculosis); Pregnants.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between extent of pulmonary disease by computed tomography and lung volumes by spirometry | High resolution computed tomography of the lungs will be evaluated by radiologists and the extent of pulmonary abnormalities will be score subjectively. Spirometry will permit assessment of lung volumes: forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). | At least one year after completion of the tuberculosis treatment |
Impact of the Surgical Experience on Cochleostomy Location: A Comparative Temporal Bone Study Between Endaural and Posterior Tympanotomy Approaches for Cochlear Implantation

Study Overview
=================
Brief Summary
-----------------
The goal of this study was to evaluate, in the hands of an inexperienced surgeon, the cochleostomy location of an endaural approach (MINV) compared to the conventional posterior tympanotomy (MPT) approach. Since 2010, the investigators use in the ENT department of Nice a new surgical endaural approach to perform cochlear implantation. In the hands of an inexperienced surgeon, the position of the cochleostomy has not yet been studied in detail for this technique. This is a prospective study of 24 human heads. Straight electrode arrays were implanted by an inexperienced surgeon: on one side using MPT and on the other side using MINV.

Official Title
-----------------
Impact of the Surgical Experience on Cochleostomy Location: A Comparative Temporal Bone Study Between Endaural and Posterior Tympanotomy Approaches for Cochlear Implantation

Conditions
-----------------
Cochlear Implantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cadaver heads person had provided written consent to give their entire body to science Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| position of the cochleostomy |  | at 1 day |
Utilisation of Angiox® in European Practice

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres. Additionally, through the collection of descriptive safety and outcomes data, this study will contribute to the Risk Management strategy for Europe

Official Title
-----------------
A Registry Study to Determine Utilisation Patterns in Patients Receiving Angiox®, and Collect Descriptive Safety and Outcome Data to Inform the Risk Management Strategy for Europe.

Conditions
-----------------
Stable Angina (SA), NSTE-ACS (NSTEMI and UA), STEMI (STE-ACS)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible for, and receive treatment with Angiox®. Willing and able to provide written informed consent to the use of their data in accordance with relevant local Data Protection laws, policies and regulations Exclusion Criteria: Participation in other interventional clinical research studies involving the evaluation of investigational drugs, including Angiox®, or devices at the time of enrolment. Patients not eligible for treatment for Angiox®.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Posology and usage patterns of Angiox®: Dose(s) and time of bolus and infusion administered |  | from hospital admission until hospital discharge, or 7 days after administration (which ever is earlier). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death Myocardial infarction Unplanned revascularisation Stroke Major* and minor bleeding Thrombocytopenia Stent thrombosis Adverse events and serious adverse events |  | measured in-hospital (prior to discharge), and at post-hospital discharge in outpatient as per local practice (30 days) |
Change and Clinical Significance of Plantar Fascia Thickness After ESWT

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the effect of extracorporeal shock wave therapy (ESWT) on the thickness of plantar fascia measured by ultrasonographic examination among patients with chronic plantar fascitis. The change of plantar fascia thickness will be correlated with clinical improvement.

Detailed Description
-----------------
The aim of the study is to investigate the effect of extracorporeal shock wave therapy (ESWT) on the thickness of plantar fascia measured by ultrasonographic examination among patients with chronic plantar fascitis. Two different dosage of ESWT will be applied, and the outcome will be followed 3 and 6 months after the treatment. The change of plantar fascia thickness will be correlated with clinical improvement, including the pain improvement, foot function, and quality of life at follow up.

Official Title
-----------------
Change and Clinical Significance of Plantar Fascia Thickness After Extracorporeal Shock Wave Therapy

Conditions
-----------------
Plantar Fasciitis

Intervention / Treatment
-----------------
* Device: Extracorporeal Shock Wave Therapy (Device)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed as plantar fasciitis for at least 6 months refractory to other conservative treatments Exclusion Criteria: Acute infection of soft tissue/bone Malignancy Epiphysiolysis in the focus Blood coagulation disorders Pregnancy Patients with pacemaker Foot deformity Autoimmune disorders-related arthropahy Sciatica Previous treatment with ESWT

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Extracorporeal Shock Wave Therapy (Device)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thickness of plantar fascia by ultrasonographic examination at 3 & 6 months |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain (visual analogue scale) at 3 & 6 months |  |  | 
| Foot function index at 3 & 6 months |  |  | 
| Short Form-36 at 3 & 6 months |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
plantar fasciitis, ultrasonographic examination